Histamine and Bradykinin Pharmacology · Module 1
Storage sites, receptor subtypes, signaling, and pathophysiological roles
Storage Sites
Immune
Mast Cells
Immune
Basophils
Gastric Mucosa
ECL Cells
CNS
Histaminergic Neurons
Receptor Subtypes
| Receptor | G Protein | Key Location | Primary Effect | Drug Target |
|---|---|---|---|---|
| H1 | Gq | Vascular endothelium, bronchial smooth muscle, sensory neurons, central nervous system | Vasodilation, increased permeability, bronchoconstriction, pruritus, wakefulness | H1 antihistamines (first- and second-generation) |
| H2 | Gs | Gastric parietal cells | Cyclic adenosine monophosphate → proton pump → acid secretion | H2 blockers (cimetidine, famotidine) |
| H3 | Gi | Presynaptic neurons, central nervous system | Inhibits histamine synthesis and release (autoreceptor) | Pitolisant (narcolepsy) |
| H4 | Gi | Immune cells | Eosinophil chemotaxis, immune modulation | No approved Step 1-level drug |
Pathophysiological Roles
Skin — H1
Triple Response of Lewis
Systemic
Anaphylaxis
High-Yield Rule — Angioedema Without Urticaria
Histamine-mediated angioedema occurs with urticaria. Bradykinin-mediated angioedema (hereditary angioedema, angiotensin converting enzyme inhibitor-induced) occurs without urticaria and does not respond to antihistamines, corticosteroids, or epinephrine. Requires bradykinin-specific therapy. See Module 4.